Ahmed Hamdy MD

Insider Reports History

Reporting-owner location: Sunnyvale, CA
Latest reporting-owner signature: /s/ Diantha Duvall, Attorney-in-fact
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Ahmed Hamdy MD

Form 4 holding CMO

CURIS INC

Security class: Employee stock option (right to buy)
Shares / value: 200,000
Estimated value: $496,000
Report date: 01 May 2025
Price: $2.48
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding CMO

CURIS INC

Security class: Common Stock
Shares / value: 66,667
Estimated value: $74,000
Report date: 20 Mar 2026
Price: $1.11
Ownership: Direct

Form 4 holding Chief Executive Officer, Director

Vincerx Pharma, Inc.

Security class: Stock Option (right to buy)
Shares / value: 200,000
Estimated value
Report date: 12 Aug 2024
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding CMO

CURIS INC

Security class: Series A Warrant (right to buy)
Shares / value: 66,667
Estimated value
Report date: 17 Mar 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding CMO

CURIS INC

Security class: Series B Warrant (right to buy)
Shares / value: 66,667
Estimated value
Report date: 17 Mar 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding CMO

CURIS INC

Security class: Series C Warrant (right to buy)
Shares / value: 66,667
Estimated value
Report date: 17 Mar 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding CMO

CURIS INC

Security class: Series B Convertible Preferred Stock
Shares / value: 0
Estimated value
Report date: 20 Mar 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Ahmed Hamdy MD

4 CRIS

CURIS INC

Report period: 20 Mar 2026
Transactions: 2
Transaction value: $0
Accepted by SEC: 23 Mar 2026, 16:03
Role: CMO
Next action: Open filing details

4 CRIS

CURIS INC

Report period: 17 Mar 2026
Transactions: 4
Transaction value: $0
Accepted by SEC: 18 Mar 2026, 16:21
Role: CMO
Next action: Open filing details

4 CRIS

CURIS INC

Report period: 01 May 2025
Transactions: 1
Transaction value: +$496,000
Accepted by SEC: 05 May 2025, 16:26
Role: CMO
Next action: Open filing details

3 CRIS

CURIS INC

Report period: 01 May 2025
Transactions: 0
Transaction value: $0
Accepted by SEC: 05 May 2025, 16:24
Role: CMO
Next action: Open filing details

4 VINC

Vincerx Pharma, Inc.

Report period: 12 Aug 2024
Transactions: 12
Transaction value: $0
Accepted by SEC: 14 Aug 2024, 20:07
Role: Chief Executive Officer, Director
Next action: Open filing details

4 VINC

Vincerx Pharma, Inc.

Report period: 23 May 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 29 May 2024, 20:54
Role: Chief Executive Officer, Director
Next action: Open filing details

4 VINC

Vincerx Pharma, Inc.

Report period: 07 Mar 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 08 Mar 2024, 20:00
Role: Chief Executive Officer, Director
Next action: Open filing details

4 VINC

Vincerx Pharma, Inc.

Report period: 09 Aug 2023
Transactions: 2
Transaction value: +$21,161
Accepted by SEC: 10 Aug 2023, 18:28
Role: President and Chief Operations Officer, Director
Next action: Open filing details

4 VINC

Vincerx Pharma, Inc.

Report period: 15 Feb 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 16 Feb 2023, 15:05
Role: Chief Executive Officer, Director
Next action: Open filing details

4 VINC

Vincerx Pharma, Inc.

Report period: 14 Dec 2022
Transactions: 1
Transaction value: +$30,538
Accepted by SEC: 14 Dec 2022, 20:22
Role: Chief Executive Officer, Director
Next action: Open filing details

4 VINC

Vincerx Pharma, Inc.

Report period: 15 Nov 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 17 Nov 2022, 15:06
Role: Chief Executive Officer, Director
Next action: Open filing details

4 VINC

Vincerx Pharma, Inc.

Report period: 25 Aug 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 29 Aug 2022, 16:05
Role: Chief Executive Officer, Director
Next action: Open filing details

4 VINC

Vincerx Pharma, Inc.

Report period: 23 Jun 2022
Transactions: 1
Transaction value: +$34,137
Accepted by SEC: 27 Jun 2022, 19:20
Role: Chief Executive Officer, Director
Next action: Open filing details

4 VINC

Vincerx Pharma, Inc.

Report period: 14 Feb 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 16 Feb 2022, 15:10
Role: Chief Executive Officer, Director
Next action: Open filing details

4 VINC

Vincerx Pharma, Inc.

Report period: 22 Dec 2021
Transactions: 1
Transaction value: +$64,650
Accepted by SEC: 27 Dec 2021, 15:28
Role: Chief Executive Officer, Director
Next action: Open filing details

4 VINC

Vincerx Pharma, Inc.

Report period: 29 Jun 2021
Transactions: 1
Transaction value: +$99,989
Accepted by SEC: 30 Jun 2021, 19:02
Role: Chief Executive Officer, Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .